Company intelligence / Profile preview
Onyvax
London, West Yorkshire, United Kingdom
- Ownership
- Private
- Development stage
- Other
01
Overview
Completed enrollment for Phase IIb clinical trial for Onyvax-P (prostate cancer vaccine) in 2008. Previous Phase IIa data showed significant slowing of PSA rise in 40% of patients and extended time to disease progression to 58 weeks compared to historical experience of 29-30 weeks[5]. Also identified a biomarker profile that could predict patient response to cancer vaccine therapy[3].
- Therapeutic areas
- Oncology
- Modalities
- Cancer vaccinesImmunotherapy
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Collaboration with John van Geest Cancer Research Centre at Nottingham Trent University[3]
Beyond the preview
Go deeper on Onyvax.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Onyvax.